In Brief
gdT cells are key regulators of effector T cell activation in pancreatic cancer and a new target for cancer immunotherapy.
INTRODUCTION
Pancreatic ductal adenocarcinoma (PDA) is a devastating disease in which the mortality rate approaches the incidence rate (Yadav and Lowenfels, 2013) . PDA is almost invariably associated with a robust inflammatory cell infiltrate, which has considerable influence on disease progression (André n- Sandberg et al., 1997; Clark et al., 2007) . Peri-pancreatic leukocytic subsets can have divergent effects on tumorigenesis by either combating cancer growth via antigen-restricted tumoricidal immune responses or by promoting tumor progression via induction of immune suppression (Zheng et al., 2013) . For example, CD8
+ T cells and Th1-polarized CD4 + T cells mediate tumor protection in murine models of PDA and are associated with prolonged survival in human disease (De Monte et al., 2011; Fukunaga et al., 2004) . Similarly, we found that negating cytotoxic CD8 + anti-tumor responses by myeloid-derived suppressor cells (MDSCs) markedly accelerates PDA growth (Pylayeva-Gupta et al., 2012) . Conversely, we recently reported that antigen-restricted Th2-deviated CD4 + T cells strongly promote PDA progression in mice (Ochi et al., 2012b) . Accordingly, intra-tumoral CD4 + Th2 cell infiltrates correlate with reduced survival in human PDA (De Monte et al., 2011; Fukunaga et al., 2004) . gdT cells are a non-major histocompatibility complex (MHC)-restricted lymphocyte subset closely aligned with innate immunity. In vitro-activated peripheral blood mononuclear cell (PBMC)-derived gdT cells have cytolytic efficacy against PDA (Oberg et al., 2014) . Conversely, a recent study showed that gdT cells produce high levels of tumor-promoting interleukin-17 (IL-17) in PDA (McAllister et al., 2014) . Nevertheless, intrapancreatic gdT cells have not been well characterized. We found that a novel population of gdT cells with a uniquely activated phenotype infiltrates the pre-neoplastic pancreas and invasive PDA in mice. In human PDA, gdT cells are a dominant T cell population comprising up to 75% of all T lymphocytes. Deletion of intra-pancreatic gdT cells markedly protects against oncogenesis in vivo and results in an influx of immunogenic Th1 cells and CD8 + T cells to the tumor microenvironment (TME). Based on these observations, we postulated that pancreas-infiltrating gdT cells promote PDA progression by inducing adaptive immune suppression. We discovered novel gdT cells cross-talk with CD4 + and CD8 + T cells implicating gdT cells as primary regulators of abT cell activation in PDA.
RESULTS

Activated gdT Cells Are Ubiquitous in Human PDA
Immunohistochemical analysis revealed that gdT cells are widely distributed within the human PDA tumor stroma but absent in normal pancreas ( Figure 1A ). Moreover, up to 75% of human PDA-infiltrating T cells were TCRg/d + compared with a much lower fraction in PBMCs ( Figure 1B ). On average, gdT cells had a similar prevalence to select myeloid-derived cellular subsets within the PDA TME ( Figure 1C ) and comprised a significantly higher percentage of tumor-infiltrating lymphocytes compared with CD8 + T cells ( Figure 1D ). Human T cell subsets, including gdT cells, can be broadly classified as central memory (T CM ) or effector memory (T EM ) based on their co-expression of CD45RA and CD27 (Sallusto et al., 2004) . We found gdT cells in PBMCs were predominantly T CM , whereas PDA-infiltrating gdT cells were mostly T EM cells, indicative of a distinctly activated phenotype ( Figure 1E ). Accordingly, tumor-infiltrating gdT cells downregulated CD62L compared with their counterparts in PBMCs ( Figure 1F ). However, Vg9 + gdT cells-associated with tumoricidal function (Izumi et al., 2013; Kunzmann et al., 2012 )-were notably absent in PDA, suggestive of tumor-permissive properties ( Figure 1G ).
A Distinctly Activated gdT Cell Population Is Prominent in Invasive and Pre-invasive Murine PDA
In vivo imaging of pancreata from C57BL/6-Trdc tm1Mal mice harboring orthotopically implanted Pdx1
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(KPC)-derived invasive PDA suggested that gdT cells were highly prevalent in the interstitial space of murine PDA ( Figure 2A ). Flow cytometry suggested a higher frequency of gdT cells infiltrating orthotopic KPC tumors compared with the spleen of tumorbearing mice ( Figure 2B ). Similar to human disease, the population of PDA-infiltrating gdT cells in mice was distinctly activated expressing higher FasL, NK1.1, CD39, CD44, JAML, and OX40 compared with spleen gdT cells ( Figure 2C ). Further, in contrast to spleen, PDA-infiltrating gdT cells contained a prominent Vg4 + subset, whereas Vg1 + cells were rare ( Figure 2C ). Tumor-infiltrating gdT cells also expressed elevated levels of IL-10 and IL-17 ( Figures 2D and 2E) . Similarly, Th1 (tumor necrosis factor a [TNF-a], interferon [IFN]-g]) and additional Th2 (IL-13) cytokines were highly expressed in PDA-infiltrating gdT cells (data not shown). Moreover, PDA-infiltrating gdT cells exhibited a substantial FoxP3 + fraction that has been associated with immune suppressive function (Kang et al., 2009 ), compared with absent expression of FoxP3 + in spleen gdT cells ( Figure S1A ). Conversely, T-bet was equally expressed in gdT cells in both compartments ( Figure S1B ). Further, PDA-infiltrating gdT cells expressed high levels of the NKG2D receptor ( Figure 2F ) as well as elevated TLR4, TLR7, and TLR9 ( Figure 2G ), which are potential avenues for cellular activation in PDA (Zambirinis et al., 2015) . CCR2, CCR5, and CCR6 were also upregulated in PDA-infiltrating gdT cells ( Figure 2H ).
To determine whether gdT cells were similarly prominent in a slowly progressive model of PDA, we interrogated pancreata of 6-month-old p48
Cre ;Kras G12D (KC) mice harboring pre-invasive tumor. gdT cells represented 6%-8% of CD3 + T cells in the pancreas of KC mice compared with 2% in the spleen and tumor-draining lymph nodes ( Figure S2A ). Further, similar to mice with invasive PDA, gdT cells expressed high levels of chemokine receptors ( Figure S2B ), Toll-like receptors (TLRs) ( Figure S2C ), and activation markers and included a prominent Vg4 + fraction ( Figure S2D ).
gdT Cell Recruitment and Activation in PDA Is Contingent on Diverse Chemokine Signaling Since we found that PDA-infiltrating gdT cells express high CCR2, CCR5, and CCR6, we postulated that ligation of these receptors is critical in their recruitment to the TME. To test this, we challenged CCR2
, and CCR6 -/-mice with orthotopic KPC-derived tumor and measured gdT cell infiltration on day 21. Deletion of CCR2, CCL2, or CCR6 significantly reduced gdT cell infiltration to the TME ( Figure S3A ). Moreover, selective CCR2, CCR5, CCR6, or CCL2 deletion mitigated TNF-a and IL-13 expression from PDA-infiltrating gdT cells whereas gdT cell expression of IL-17 and IFN-g were not affected ( Figures S3B-S3E ). gdT cell expression of FoxP3 or IL-10 was similarly not perturbed by blockade of chemokine signaling (data not shown).
gdT Cells Promote Pancreatic Oncogenesis Since gdT cells are a prominent lymphocytic subset within the pancreatic TME, we postulated that they play a critical role in oncogenesis. To test this, we crossed KC mice with Tcrd -/-mice. Pancreata of KC;Tcrd -/-mice were protected from progressive oncogenesis exhibiting a diminished rate of acinar replacement by dysplastic ducts and substantially slower PanIN progression at multiple time points ( Figure 3A) . Analysis of pancreas weights confirmed the protective effects of gdT cell deletion ( Figure 3B ). gdT cell ablation was also associated with reduced peri-tumoral fibrosis ( Figure 3C ). Moreover, KaplanMeier analysis revealed a nearly 1-year increase in the median survival of gdT cell-deficient KC mice compared with controls ( Figure 3D ).
Since genetic deletion of gdT cells has limited translational applicability to human disease, we tested whether in vivo depletion of Vg4 + gdT cells using a neutralizing monoclonal antibody (mAb) would offer similar protection ( Figure S3F ). We treated 6-week-old KC mice for 8 weeks with UC3-10A6 or isotype control and assessed their effects on tumorigenesis. gdT cell depletion protected against oncogenic progression based on histological analysis of ductal transformation ( Figure 3E ) and tumor mass ( Figure 3F ). To determine whether the presence of gdT cells are similarly associated with accelerated tumorigenesis in an invasive model of PDA, we orthotopically implanted KPCderived tumor cells into the pancreatic body of wild-type (WT) and Tcrd -/-mice. Consistent with our data in KC mice, deletion of gdT cells impressively protected against tumor growth and extended survival in the orthotopic KPC model (Figures S3G and S3H) . gdT cell depletion similarly extended survival in invasive PDA ( Figure S3G ). Moreover, blocking gdT cell recruitment and activation using mice deficient in selective chemokine signaling was also protective ( Figure S3I ). Notably, disease phenotype in caerulein-induced pancreatitis was not mitigated in Tcrd -/-mice suggesting that the ability of gdT cells to modulate pancreatic disease is specific to PDA (Figures S4A-S4G ). Figure S4H ) or deregulate expression of oncogenic or tumor suppressor genes ( Figure S4I ) in transformed epithelial cells. Similarly, gdT cell co-culture did not elicit pro-inflammatory or regulatory cytokine production from tumor cells suggesting that PDA-infiltrating gdT cells do not promote tumorigenesis via direct engagement of cancer cells ( Figure S4J ). 5D ). Collectively, these data suggest immunogenic reprogramming of adaptive abT lymphocytes in PDA in the absence of gdT cells.
To determine whether gdT cells similarly delimit abT cell expansion and activation in a slowly progressive model of PDA, we compared CD4 + and CD8 + T cell phenotype in KC;Tcrd +/+ versus KC;Tcrd -/-pancreata. We found that while CD4 + and CD8 + T cells were scarce in KC;Tcrd +/+ controls, both lymphocyte populations were markedly expanded in KC;Tcrd -/-pancreata ( Figures S5A and S5B ). Further, both CD4 + and CD8 + T cells in PDA-draining lymph nodes expressed higher CD44 ( Figure S5C ) and PD-1 ( Figure S5D Figure S5E ). Moreover, similar to the orthotopic KPC model, pancreas-draining CD4 + and CD8 + T cells in KC mice upregulated IFN-g ( Figure S5F ) and T-bet ( Figure S5G ) in the context of gdT cell deletion, whereas CD4 + T cell expression of GATA-3 and FoxP3 were unaffected by gdT cell deletion (Figures S5H and S5I) .
To definitively test whether enhanced abT cell immunogenicity accounts for the protection against PDA observed in gdT celldeficient animals, we depleted CD4 + and CD8 + T cells in Tcrd -/-mice and WT controls coincident with KPC-derived orthotopic tumor challenge. Ablation of abT cell populations did not accelerate tumor growth in WT hosts but completely reversed the tumor-protective effects of gdT cell deletion. These data suggest that tumor protection in PDA-bearing Tcrd -/-mice is mediated by abT cells ( Figure 5E ). To test whether PDA-infiltrating gdT cell inhibition of CD4 + and CD8 + T cells requires direct cellular interaction, we activated spleen abT cells in vitro using CD3/CD28 co-ligation alone or in the context of either co-culture with PDA-derived gdT cells or admixture with gdT cell-conditioned media. Direct gdT cell coculture prevented CD4 + and CD8 + T cells from adopting an activated CD44 + CD62L -phenotype (Figures S6A and S6B) and expressing immune-modulatory cytokines ( Figures S6C-S6E) ; however, gdT cell-conditioned media was non-inhibitory. These data suggest that gdT cells do not inhibit abT cells via secreted factors but require direct cellular interaction.
Pancreas-Infiltrating gdT Cells Express High T Cell Exhaustion Ligands
We postulated that gdT cells may directly inhibit CD4 + and CD8 + T cell activation. We discovered that PDA-infiltrating gdT cells in KC mice expressed high PD-L1 ( Figure 6A ) and compared with absent expression of these ligands in spleen gdT cells. Similarly, gdT cells in orthotopic KPC tumors also expressed elevated PD-L1 and Galectin-9 ( Figure 6C ). Expression levels of PD-L1 and Galectin-9 in PDA-infiltrating gdT cells were markedly higher than in cancer cells and comparable with that of tumor-infiltrating myeloid cell populations (Figure 6C) . By contrast, PDA-infiltrating gdT cells expressed elevated B7-1 but low levels of other activating ligands including B7-2, ICOSL, and OX40L in orthotopic KPC ( Figure 6D ) and KC (data not shown) tumors. Exhaustion ligand expression in myeloid or tumor cells in PDA was not affected by gdT cell (legend continued on next page) deletion ( Figure 6E ). Notably, besides regulating gdT cell expansion and activation, CCR2, CCR5, and CCR6 signaling were necessary for gdT cell expression of PD-L1 or Galectin-9 ( Figures  6F and 6G ). To determine whether these findings translated to human disease, we tested PD-L1 expression in human PDA. Remarkably, PBMC gdT cells in PDA patients expressed elevated PD-L1 compared with absent PD-L1 expression in PBMC gdT cells from healthy subjects ( Figure 6H ). Moreover, PD-L1 was expressed in 50% of tumor-infiltrating gdT cells in human PDA ( Figure 6H ). Similarly, Galectin-9 was upregulated in human PDA-infiltrating gdT cells ( Figure 6I ).
gdT Cells Inhibit abT Cell Activation via Checkpoint Receptor Ligation Previous reports have shown that low PD-L1 expression is associated with improved survival in human PDA and that PD-L1 blockade in murine PDA protects mice longitudinally (Nomi et al., 2007) . We postulated that gdT cells promote PDA progression by preventing abT cell activation via checkpoint receptor ligation. To test this, we again activated spleen CD4 + and CD8 + T cells in vitro using CD3/CD28 co-ligation alone or in the context of co-culture with PDA-derived gdT cells. Similar to our previous experiments, gdT cells prevented CD4 + (Figure 7A) and CD8 + ( Figure 7B ) T cells from adopting an activated CD44 + CD62L -phenotype; however, gdT cell-mediated suppression was reversed with PD-L1 blockade. Further, whereas PDA-infiltrating gdT cells prevented abT cell expression of TNF-a in vitro, this was again reversed by PD-L1 blockade ( Figure 7C ). To definitively test whether gdT cells promote PDA progression in vivo via checkpoint-ligand-dependent immune suppression, we serially blocked PD-L1 or Galectin-9 using neutralizing mAbs in cohorts of WT and Tcrd -/-mice challenged with orthotopic KPC-derived tumor. Consistent with our hypothesis, PD-L1 or Galectin-9 blockade protected WT mice but were ineffective at further inducing tumor protection in Tcrd -/-animals ( Figure 7D ). Moreover, aPD-L1 and aGalectin-9 each substantially increased abT cell infiltration of PDA in WT mice ( Figure 7E ) but failed to enhance abT cell infiltration in Tcrd -/-hosts (data not shown). Similarly, both PD-L1 and Galectin-9 blockade in vivo induced an activated CD4 + and CD8 + T cell phenotype in orthotopic PDA in WT mice but did not enhance abT cell activation or Th1 polarization in PDA in Tcrd -/-hosts ( Figures 7F, 7G , S6F, and S6G). To determine whether checkpoint ligand antagonism was also only efficacious in gdT cell-competent hosts in a slowly progressive model of PDA, we serially treated cohorts of 6-week-old KC;Tcrd +/+ and KC;Tcrd -/-mice for 8 weeks with an aPD-L1
mAb. Again, PD-L1 inhibition protected KC pancreata from oncogenic progression but offered no benefit in KC;Tcrd -/-mice ( Figure S6H ). Moreover, adoptive transfer of PDA-entrained gdT cells to Tcrd -/-mice coincident with orthotopic tumor challenge resulted in tumor growth rates comparable to WT mice ( Figure S6I ). However, ex vivo blockade of PD-L1 in gdT cells prior to adoptive transfer failed to accelerate tumor growth ( Figure S6J ). To determine whether PDA-infiltrating gdT cells abrogate antigen-restricted anti-tumor immunity in a PD-L1-dependent manner, we directly inoculated PDA-infiltrating gdT cells into established subcutaneous PDA tumors engineered to express OVA in Tcrd -/-hosts. gdT cell administration again accelerated tumor growth and concomitantly diminished OVAspecific CD8 + T cell proliferation and activation. However, ex vivo blockade of PD-L1 blockade in gdT cells abrogated their tumor-promoting and immune-suppressive effects ( Figures  S6K-S6M ). Collectively, these data imply gdT cells are important mediators of checkpoint-receptor-dependent immune suppression in PDA. Notably, whereas gdT cell deletion augmented abT cell infiltration and activation in PDA, it did not alter the fraction of PDAinfiltrating MDSCs or tumor-associated macrophages (TAMs) ( Figure S7A) . Similarly, gdT cell deletion did not affect the capacity of MDSCs or TAMs to mitigate T cell proliferation in PDA ( Figures S7B and S7C) . Further, in contrast to the exhaustion ligand-dependent immune-suppressive effects of gdT cells, PDA-infiltrating MDSC inhibition of abT cell activation was independent of PD-L1 and macrophage-mediated inhibition was only partially mitigated by PD-L1 blockade based on aCD3/aCD28-mediated abT cell proliferation ( Figures S7B and S7C) , expression of TNF-a ( Figures S7D and S7E) , and adoption of a CD44 + CD62L -phenotype (data not shown). Moreover, whereas abT cells were in intimate proximity with gdT cells in the PDA TME, myeloid cells were separated by great distances from abT cells in situ in human PDA ( Figure S7F ), in invasive murine PDA ( Figure S7G ) and in pre-invasive disease (data not shown) suggesting enhanced opportunity for direct gdT cell-abT cell interaction and limited opportunity for direct cross-talk between macrophages and abT cells. Similarly, whereas abT cells were in direct contact with PD-L1 + gdT cells ( Figure S7H ), abT cells were not in close proximity of PD-L1 + epithelial cells ( Figure S7I ).
DISCUSSION
Immune suppressive inflammation is paramount for PDA progression. Murine modeling of PDA using animals that endogenously express pancreas-specific oncogenic Kras revealed that pancreatic dysplasia is preceded by and accompanied by vigorous pancreatitis (Hingorani et al., 2003) . Moreover, a driving oncogenic mutation alone is insufficient for disease progression and concomitant pancreatitis is necessary for PDA development (Guerra et al., 2007) . The peri-pancreatic immune infiltrate is rife with immune-suppressive elements that support oncogenesis. In particular, innate immune cells within the TME are apt at educating adaptive immune effectors toward a tumor-permissive phenotype. Antigen presenting cell (APC) populations, including M2-polarized TAMs and myeloid dendritic cells, induce the generation of PDA-promoting Th2 cells over Th1 cells that facilitate cytotoxic T lymphocytes (CTLs) (Ochi et al., 2012b; Zhu et al., 2014) . Similarly, we and others have shown that Effector T cells are also thought to be excluded from the PDA TME by CXCL12 produced by a subset of carcinoma-associated fibroblasts which express fibroblast activation protein (FAP) (E) WT and Tcrd -/-pancreata were orthotopically implanted with KPC-derived tumor cells and serially treated with a-CD4 and a-CD8 neutralizing mAbs or isotype controls. Pancreatic tumors were harvested at 3 weeks. Representative images and tumor weights are shown (n = 5/group; *p < 0.05, **p < 0.01, ***p < 0.001). (Feig et al., 2013) . However, a comprehensive understanding of the basis for T cell scarcity and poor immunogenicity in PDA is lacking. gdT cells have not been well characterized in PDA, and their role in the programming of the TME remains ill defined. We found that gdT cells are pervasive in human and murine PDA and tumor infiltration with gdT cells promotes oncogenic progression whereas genetic deletion, therapeutic depletion, and blockade of recruitment of gdT cells markedly delays morphologic transformation of the pancreas and increases median animal survival by nearly one year in a slowly progressive model of PDA. In contrast to our findings, gdT cells have long been considered potent anti-tumor entities in diverse tumor subtypes (Cordova et al., 2012; Todaro et al., 2009 ). In melanoma, renal cell cancer, and colon cancer, the putative protective effects of gdT cells have led to strategies employing exogenous activation of gdT cells to maximize their tumoricidal activity in vivo (Gao et al., 2003; Girardi et al., 2001 ; Lanç a and Silva-Santos, 2012). While our findings are ostensibly paradoxical to the described function of gdT cells in these cancer models, we demonstrate that the gdT cells in PDA exhibit a unique phenotype. Most interestingly, PDA-infiltrating gdT cells express substantial FoxP3, which is absent in spleen gdT cells from the same animals. Endogenous FoxP3 expression in gdT cells has not been previously reported. However, FoxP3 can be induced in gdT cells upon in vitro stimulation with TGF-b in combination with TCRgd ligation (Kang et al., 2009 ). Resultant FoxP3 + gdT cells are potently suppressive to T cell activation and proliferation. We found that chemokine signaling does not influence gdT cell expression of FoxP3 in PDA. However, we and others have shown that the PDA TME is rife with TGF-b which can possibly induce FoxP3 expression (Goggins et al., 1998; Greco et al., 2015) . Also consistent with a tumor-permissive phenotype, human PDA-infiltrating gdT cells do not express the Vg9 TCR whose ligation has been implicated in the direct tumoricidal activity of gdT cells in melanoma and colon cancer (Izumi et al., 2013; Kunzmann et al., 2012) .
While most early reports suggested that gdT cells were notable for their anti-cancer properties, emerging data suggest that gdT cells can have pro-tumorigenic effects. Select subsets of tumor infiltrating gdT cells in breast cancer block the maturation of TLR8-sensitive dendritic cells and their capacity to prime abT cells (Peng et al., 2007) . In murine B16 melanoma, Vg4 + and Vg1 + subsets of gdT cells reportedly have opposing roles in tumorigenesis with Vg4 + cells mediating protective anti-tumor immunity via IFN-g and perforin, whereas Vg1 + cells produce tumor-permissive Th2-family cytokines (Hao et al., 2011) . By contrast, in PDA we found that tumor-promoting gdT cells are almost exclusively Vg4 + Vg1 -. Coffelt et al. showed in breast cancer models that IL-17 expression from gdT cells results in G-CSFdependent expansion of neutrophils which acquire the ability to suppress anti-tumor CTL activity (Coffelt et al., 2015) . Similarly, IL-17 production by gdT cells in murine hepatocellular carcinoma and colorectal cancer models mediates MDSC infiltration and their subsequent inhibition of cytotoxic CD8 + T cells Wu et al., 2014) . By contrast, we demonstrate that deletion of gdT cells in PDA does not influence the fraction of myeloid cells in the TME, nor does it affect their functional capacity to suppress T cell proliferation. Consistent with recent reports, we show that PDA-infiltrating gdT cells express high IL-17, which can directly promote pancreatic oncogenesis via ligation of IL-17R on transformed epithelial cells (McAllister et al., 2014; Wu et al., 2015) . However, our cumulative data suggest that IL-17 may not be critical to the pro-tumorigenic effects of PDA-infiltrating gdT cells since blockade of select chemokine signaling mitigated gdT cell infiltration, activation, and exhaustion ligand expression and was protective against PDA despite IL-17 expression being unaffected. Further, our in vitro correlative studies suggested that secreted factors in gdT cell conditioned media were non-inhibitory to CD4 + and CD8 + T cell activation. We demonstrate that gdT cells create an immune-suppressive adaptive TME through checkpoint receptor ligation in tumor-infiltrating abT cells. Deletion of gdT cells in PDA results in a robust influx of CD4 + and CD8 + T cells. Furthermore, in the absence of gdT cells, CD4 + T cells exhibit accentuated Th1 differentiation and CD8 + T cells exhibit a heightened cytotoxic phenotype.
Moreover, whereas deletion of CD4 + and CD8 + T cells did not accelerate tumor progression in gdT cell-competent hosts, abT cell deletion nearly tripled the rate of PDA growth in Tcrd -/-mice. This observation supports the notion that abT cells are entirely dispensable in PDA but are reprogramed into powerful anti-tumor entities in the absence of gdT cells.
The volume of T cell exhaustion ligand levels in carcinomas, including in PDA, has been largely attributed to expression from tumor cells and macrophages (Nomi et al., 2007; Sharma and Allison, 2015) . However, we show that gdT cells express considerably higher levels of PD-L1 and Galectin-9 in PDA than cancer cells. More importantly, we demonstrate that gdT cells are important contributors to PD-L1 and Galectin-9-induced T cell exhaustion in the TME based on our observation that inhibition of PD-L1 and Galectin-9 in PDA is protective in vivo in the presence of gdT Representative histograms and quantitative data are shown (n = 11 patients; *p < 0.05, **p < 0.01, ***p < 0.001).
cells, whereas in absence of gdT cells PD-L1 or Galectin-9 blockade offers no additional tumor-protective benefit. Even more, PD-L1 or Galectin-9 blockade expand and potently activate PDA-infiltrating CD4 + and CD8 + T cells in gdT cell-competent hosts but do not enhance abT cell immunogenicity in the absence of gdT cells. It is perhaps surprising that checkpoint receptor blockade would not have potency in Tcrd -/-mice considering the substantial myeloid cell infiltrate in PDA (Liou et al., 2015; Pylayeva-Gupta et al., 2012) . Indeed, we found that myeloid cells from Tcrd -/-mice have equivalent T cell inhibitory capacity to their cellular counterparts in WT mice. However, we found that, whereas abT cells are in intimate proximity to gdT cells in the PDA TME, myeloid cells are separated by great distances from abT cells in situ in human PDA, invasive murine PDA, and pre-invasive disease suggesting enhanced opportunity for gdT cell-abT cell interaction and limited opportunity for direct crosstalk between macrophages and abT cells. Further, tumor cell expression of exhaustion ligands is also possibly of lesser significance as T cells are excluded from direct contact with tumor cells via CXCL12 produced from FAP-expressing carcinoma-associated fibroblasts in PDA (Feig et al., 2013; Joyce and Fearon, 2015) . Collectively, these data may suggest that abT cells are prevented from having immunogenic relevance in PDA via a ''double-hit'': fibroblast-mediated chemokine signaling excludes abT cells from the direct tumor environs where gdT cells serve to check their activation via ligation of inhibitory receptors. In summary, we show that PDA-infiltrating gdT cells are a highly influential lymphocyte subset in human and murine PDA, which promote pancreatic oncogenesis and reduce survival via novel cross-talk with the adaptive immune compartment. These data implicate gdT cells as high-yield targets for the development of experimental therapeutics in PDA and has potential implications for the mechanistic progression of oncogenesis in other cancer subtypes. Finally, gdT cells may have prognostic significance in PDA and may be predictive of response to immunotherapeutic regimens.
STAR+METHODS
Detailed methods are provided in the online version of this paper and include the following: 
STAR+METHODS CONTACT FOR REAGENT AND RESOURCE SHARING
Further information and requests for reagents may be directed to and will be fulfilled by the corresponding author George Miller (george.miller@nyumc.org). ) mice were purchased from Jackson Labs (Bar Harbor, ME). KC mice (gift of D. Bar-Sagi), which develop pancreatic neoplasia endogenously by expressing mutant Kras, were generated by crossing LSL-Kras G12D and p48 Cre mice (Hingorani et al., 2003) . Tcrd -/-mice were crossed with KC mice to generate KC;Tcrd -/-animals. Both male and female mice were used but animals were sex-and agematched in each experiment. Randomization was not performed. There were no specific inclusion or exclusion criteria. Sample sizes for experiments were determined without formal power calculations. Data for control KC mice have been previously reported (Seifert et al., 2016) . For orthotopic tumor challenge, mice were administered intra-pancreatic injections of tumor cells derived from KPC mice (1x10 5 cells in Matrigel) and sacrificed at 3 weeks as described (Zambirinis et al., 2015) . For subcutaneous tumor challenge, KPC-derived tumor cells (1x10 6 ) engineered to express OVA using pCI-neo-cOVA (gift of Maria Castro; Addgene plasmid # 25097) were administered to the flanks of mice (Yang et al., 2010) . In select experiments, FACS-sorted PDA-infiltrating gdT cells were orthotopicaly transferred (8x10 5 ) together with tumor cells or directly inoculated into subcutaneous tumors ( 3x10 5 ). In other experiments, animals were treated twice weekly with i.p. injection of neutralizing mAbs directed against TCR Vg4 (UC3-10A6, 8mg/kg), PD-L1 (10F.9G2, 5mg/kg), or Galectin-9 (RG9-1, 6mg/kg; all BioXCell, West Lebanon, NH). In select experiments CD4 (GK1.5; BioXCell) or CD8 (53-6.72; Monoclonal Antibody Core Facility, Sloan Kettering Institute, New York, NY) T cells were depleted using previously described regimens (Bedrosian et al., 2011) . Acute pancreatitis was induced using a regimen of seven hourly i.p. injections of caerulein (50 mg/kg; Sigma, St. Louis, MO) for two consecutive days as we have described (Bedrosian et al., 2011) . Serum amylase and lipase levels were measured using commercial kits (Sigma) according to the manufacturer's instructions. Animal procedures were approved by the NYU School of Medicine IACUC.
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Human and Murine Cellular Isolation
Pancreatic leukocytes were harvested from mouse PDA as described previously (Ochi et al., 2012a) . Briefly, pancreata were resected in total and placed in ice-cold PBS with 1% FBS with Collagenase IV (1 mg/mL; Worthington Biochemical, Lakewood, NJ) and DNase I (2 U/mL; Promega, Madison, WI). After mincing, tissues were incubated in the same solution at 37 C for 30 min with gentle shaking. Specimens were passed through a 70 mm mesh, and centrifuged at 350 g for 5 min. Human pancreatic tissues and PBMC were collected under an IRB approved protocol and donors of de-identified specimens gave informed consent. Sample sizes for human experiments were not determined based on formal power calculations. Human pancreatic leukocytes were prepared in a similar manner to mice. PBMC were isolated by overlaying whole blood diluted 3:1 in PBS over an equal amount of Ficoll (GE Healthcare, Princeton, NJ). Cells were then centrifuged at 2100 RPM and the buffy coat harvested as we have described (Rehman et al., 2013) . using an H-2kb SIINFEKL OVA Pentamer (ProImmune, Oxford, United Kingdom). Intracellular staining was performed using the FoxP3 Fixation/Permeabilization Solution Kit (eBiosciences). Analysis of human cells was performed using fluorescently conjugated antibodies directed against CD45 (HI30), CD3 (SK7), CD45RA (HI100), CD27 (O323), CD62L (DREG-56), CD14 (HCD14), PD-L1 (29E.2A3), Galectin 9 (9M1-3), CD15 (W6D3), CD11c (3.9), Vg9 (B3; all Biolegend), Tcrg/d (B1.1; eBioscience). Flow cytometry was performed on the LSR-II (BD Biosciences, Franklin Lakes, NJ). Cytokine levels in cell culture supernatant were measured using a cytometric bead array (BD Biosciences). FACS-sorting was performed on the SY3200 (Sony, Tokyo, Japan). Data were analyzed using FlowJo (Treestar, Ashland, OR).
METHOD DETAILS
Western Blotting
Cells or tissues were lysed in ice-cold RIPA buffer. Total protein was quantified using the BioRad DC Protein Assay according to the manufacturer's instructions (BioRad, Hercules, CA). Western blotting was performed as described previously with minor modifications (Ochi et al., 2012a) . Briefly, 10% Bis-Tris polyacrylamide gels (NuPage; Invitrogen, Carlsbad, CA) were equiloaded with 10-30 mg protein, electrophoresed at 200 V and electrotransferred to PVDF membranes. After blocking with 5% BSA, membranes were probed with primary antibodies to Bcl-XL (54H6), Rb (D20), c-Myc (D84C12), PTEN (26H9), p53 (1C12), and b-actin (8H10D10), all Cell Signaling, Beverly, MA. Blots were developed by ECL (Thermo Scientific, Asheville, NC).
Histology, Immunohistochemistry, and Microscopy
For histological analysis, pancreatic specimens were frozen in OCT medium or fixed with 10% buffered formalin, dehydrated in ethanol, embedded with paraffin, and stained with H&E or Gomori's Trichrome. The fraction of preserved acinar area was calculated as previously described (Ochi et al., 2012a) . The fraction and number of ducts containing all grades of PanIN lesions was measured by examining 10 high-power fields (HPFs; 40X) per slide. PanINs were graded according to established criteria (Hruban et al., 2001 ): In PanIN I ducts, the normal cuboidal pancreatic epithelial cells transition to columnar architecture (PanIN Ia) and gain polyploid morphology (PanIN Ib). PanIN II lesions are associated with loss of polarity. PanIN III lesions, or in situ carcinoma, show cribriforming, budding off of cells, and luminal necrosis with marked cytological abnormalities, without invasion beyond the basement membrane. Slides were evaluated by an expert pancreas pathologist (CH). Immunohistochemistry (IHC) was performed using antibodies directed against CD4 (RM4-5; BD Bioscience), CD8 (YTS169.4; Abcam), GFP (D5.1; CellSignaling) and TCRg/d (B1; Biolegend). Quantifications were performed by assessing 10 HPF per slide. For immunofluorescent staining, frozen specimens were probed with antibodies directed against TCRg/d (GL3; Biolegend), TCRab (H57-597; Biolegend), PD-L1 (Polyclonal, Abcam), CK19 (Troma-III; University of Iowa) or CD11b (M1/70; Biolegend). For analysis of human tissues, frozen sections of human pancreatic cancer specimens were probed with antibodies directed against TCRg/d (B1.1; eBioscience), TCRab (IP26; Biolegend), or CD11b (M1/70; Biolegend). Images were acquired using the Zeiss LSM700 confocal microscope along with ZEN software (Carl Zeiss, Thornwood, New York). The proximity of abT cells to gdT cells or CD11b + cells, respectively, was determined by measuring the distance between each abT cell and its spatially closest counterpart. Distances were measured in micrometers on low power fields (20X). The averages distances were calculated for 10 low power fields per pancreas.
Intravital Imaging
Orthotopic pancreas tumor-bearing C57BL/6-Trdc tm1Mal mice were anesthetized and a left subcostal laparotomy incision was made. The spleen and pancreatic tumor were externalized. The mouse was then placed prone on a heated (37 C) stage mounted with a coverslip which was in contact with the pancreatic tumor. To visualize the pancreatic vasculature, mice were injected i.v. with 25 mg Evan Blue (Sigma) 10 min before imaging. Images were acquired with a LSM 710 inverted microscope (Zeiss) with a MaiTai Ti:Sapphire laser (Spectra-Physics, Santa Clara, CA) tuned to 910-930 nm. Emitted fluorescence was detected through 420/40, 465/30, 520/30, 575/70, and 660/50 nm band-pass filters and nondescanned detectors to generate second harmonic signals (collagen fibers) and 4-color images. All the images were acquired at least 50 mm below the tumor capsule. ZEN software was used for analysis.
In Vitro T Cell Activation Assays For T cell activation assays, spleen CD4 + or CD8 + T cells (5x10 4 ) were labeled with CFSE (eBioscience) and plated alone or with PDAinfiltrating gdT cells, MDSC, or TAMs (5:1 ratio) in 96 well plates coated with anti-CD3 (145-2C11, 10mg/ml) and anti-CD28 (37.51; 10mg/ml, both Biolegend). After 72 hr, abT cells were harvested and analyzed by flow cytometry. In selected experiments, cells were treated with a neutralizing mAb directed against PD-L1 (10F.9G2, 10mg/ml; BioXCell).
QUANTIFICATION AND STATISTICAL ANALYSIS Statistical Analysis
Data is presented as mean ± standard error. Survival was measured according to the Kaplan-Meier method. The sample size for each experiment, n, is included in the results section and the associated figure legend. Statistical significance was determined by the Student's t test and the Wilcoxon test using GraphPad Prism 6 (GraphPad Software, La Jolla, CA). P-values < 0.05 were considered significant. P values for each experiment are also included in the associated figure legends. Figure S1 . PDA-Infiltrating gdT Cells Express Elevated FoxP3, Related to Figure 2 (A and B) WT mice were orthotopically implanted with KPC-derived tumor cells. On day 21, splenic and PDA-infiltrating CD3 + T lymphocytes were co-stained for (A) CD4, TCRgd, and FoxP3 or (B) CD4, TCRgd, and T-bet. Representative contour plots and quantitative data from 5 mice per group are shown (*p < 0.05). Experiments were repeated twice with similar results.
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